Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 7/20 | 0.55 |
| ▸ | TP53 | P04637 | 4/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26601264 | 0.91 | MAPT (0.60) | POLBMAPTLMNATP53RXFP1 | |
| SCHEMBL26601352 | 0.85 | KDM4E (0.50) | POLBMAPTLMNATP53RXFP1 | |
| SCHEMBL30670761 | 0.84 | POLB (0.64) | POLBMAPTLMNATP53RXFP1 | |
| SCHEMBL26601325 | 0.84 | POLB (0.64) | POLBMAPTLMNATP53RXFP1 | |
| SCHEMBL26601350 | 0.83 | LMNA (0.57) | POLBMAPTLMNATP53RXFP1 | |
| SCHEMBL26601053 | 0.83 | LMNA (0.67) | POLBMAPTLMNATP53THRB | |
| SCHEMBL26601300 | 0.82 | LMNA (0.65) | POLBMAPTLMNATP53RXFP1 | |
| SCHEMBL30670756 | 0.81 | LMNA (0.57) | POLBMAPTLMNATP53RXFP1 | |
| SCHEMBL26601138 | 0.81 | LMNA (0.57) | POLBMAPTLMNATP53RXFP1 | |
| SCHEMBL26601368 | 0.81 | KDM4E (0.54) | POLBMAPTLMNATP53RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250281483-A1 | TRANSCRIPTION FACTOR EB ACTIVATORS AND USES THEREOF | Astellas Engineered Small Molecules US, Incorporated | 2025-09-11 | — | — | US | disclosed |
| EP-4511112-A1 | TRANSCRIPTION FACTOR EB ACTIVATORS AND USES THEREOF | Astellas Engineered Small Molecules US, Incorporated (US) | 2025-02-26 | — | — | EP | disclosed |
| WO-2023205415-A1 | TRANSCRIPTION FACTOR EB ACTIVATORS AND USES THEREOF | MITOBRIDGE INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023205415-A1 | TRANSCRIPTION FACTOR EB ACTIVATORS AND USES THEREOF | MITOBRIDGE INC. (US) | 2023-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250281483-A1 | TRANSCRIPTION FACTOR EB ACTIVATORS AND USES THEREOF | TFEB, MITF, CREBBP | POLB 868/4885MAPT 918/4885LMNA 852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.